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Abstract
Background: Recent guidelines recommend assessment and treatment of the overall risk for
cardiovascular disease (CVD) through management of multiple risk factors in patients at high
absolute risk. The aim of our study was to assess the level of cardiovascular risk in patients with
known risk factors for CVD by applying the SCORE risk function and to study the implications of
European guidelines on the use of treatment and goal attainment for blood pressure (BP) and lipids
in the primary care of Cyprus.
Methods: Retrospective chart review of 1101 randomly selected patients with type 2 diabetes
mellitus (DM2), or hypertension or hyperlipidemia in four primary care health centres. The SCORE
risk function for high-risk regions was used to calculate 10-year risk of cardiovascular fatal event.
Most recent values of BP and lipids were used to assess goal attainment to international standards.
Most updated medications lists were used to compare proportions of current with recommended
antihypertensive and lipid-lowering drug (LLD) users according to European guidelines.
Results: Implementation of the SCORE risk model labelled overall 39.7% (53.6% of men, 31.3% of
women) of the study population as high risk individuals (CVD, DM2 or SCORE ≥5%). The SCORE
risk chart was not applicable in 563 patients (51.1%) due to missing data in the patient records,
mostly on smoking habits. The LDL-C goal was achieved in 28.6%, 19.5% and 20.9% of patients with
established CVD, DM2 (no CVD) and SCORE ≥5%, respectively. BP targets were achieved in
55.4%, 5.6% and 41.9% respectively for the above groups. There was under prescription of
antihypertensive drugs, LLD and aspirin for all three high risk groups.
Conclusion: This study demonstrated suboptimal control and under-treatment of patients with
cardiovascular risk factors in the primary care in Cyprus. Improvement of documentation of clinical
information in the medical records as well as GPs training for implementation and adherence to
clinical practice guidelines are potential areas for further discussion and research.
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Background
Cardiovascular disease (CVD) is the major cause of pre-
mature death in most European populations [1]; it is an
important source of disability and contributes to the esca-
lating costs of health care [2]. In Cyprus, CVD accounts for
41% of all annual deaths with slight decline in mortality
over the last decade [3]. Recent European guidelines stress
the importance of integrated cardiovascular risk predic-
tion in planning preventive strategies [1]. The first and
most widely used risk prediction tools were developed
with data from the Framingham Heart Study [4]. How-
ever, several studies have shown that when Framingham
risk charts, derived from a northern American population,
are applied to European populations they tend to overes-
timate the risk of an event [5-7]. In 2003, the European
guidelines on CVD prevention, recommended the SCORE
(Systematic Coronary Risk Evaluation) risk model as a
tool in everyday practice [1]. The SCORE system was
developed by the SCORE project group [8] who assem-
bled a pool of datasets from 12 European cohort studies
in order to calculate separate risk functions for high and
low risk regions of Europe. One of the advantages of using
the SCORE database for risk assessment is that it can be
easily adapted to national conditions, resources and prior-
ities and takes into account the heterogeneity in CVD
mortality across European populations [1]. Furthermore it
is a relevant tool to general practice where most primary
prevention of Coronary Heart Disease (CHD) and man-
agement of people with risk factors take place.
Recently the updated version of the European Guidelines
on CVD prevention was issued by the Fourth Joint Task
Force [9] redefining priorities and objectives on the pre-
vention of CVD.
In Cyprus, a new National Health System (NHS) will be
introduced at the end of 2008. Among other tasks, GPs
will have a major role in the management of patients with
chronic diseases as well as in the development of preven-
tion strategies in order to promote the well being of
patients with high risk behaviours and of the population
in general. In the context of this reform and prior to the
introduction of the NHS a collaborative project was devel-
oped with the Clinic of Social and Family Medicine of the
University of Crete. One of the goals was to improve the
performance of General Practitioners (GPs) in the man-
agement of patients with chronic diseases through train-
ing and research programs.
The aim of this study which was part of the aforemen-
tioned collaboration was to assess the proportion of high
risk patients by applying the SCORE risk model in a
cohort of patients with known risk factors for CVD in four
Primary Care Health Centres in Cyprus. Another objective
was to describe the implications of these guidelines for
high risk groups with regard to goal attainment of blood
pressure and lipids and to compare recommended and
current use of antihypertensives and/or lipid lowering
drugs.
Methods
This study was a retrospective cohort analysis of the med-
ical records of selected patients in four Primary Care
Health Centres (PCHCs) in Cyprus. The PCHCs enrolled
in the study – two urban and two rural – were located in
the Nicosia area and were selected using specific selection
criteria. Selection was based on the size of the population
served by each PCHC, the opening hours of the PCHC, the
number of GPs as well as their postgraduate education
and years of experience in primary healthcare (PHC) and
the number of nurses and administrative staff at each
PCHC.
Study participants
Of the 9504 charts available, 4633 patients with the diag-
nosis of type 2 diabetes mellitus (DM2), or hypertension
or hyperlipidemia were identified. We made a random
selection of 1101 patients and reviewed their medical
records in order to assess provided care during the year
2002. Patients less than 18 years of age and those who had
no visits during the year examined were excluded from the
study.
Definitions
Hypertension was considered present if the diagnosis
hypertension was documented in the medical file, or if the
patient was on antihypertensive medication or if there
were recordings of at least two consecutive measurements
of Systolic Blood Pressure (SBP) ≥140 mmHg and/or
Diastolic Blood Pressure (DBP) ≥90 mmHg in the medical
records within the year examined [10].
DM2 was considered present if the diagnosis of DM2 was
registered in the medical record or by documentation of
oral hypoglycemic drugs or combination of oral hypogly-
cemic drugs and insulin in the medication list or if a fast-
ing plasma glucose (FPG) level ≥126 mg/dl (7.0 mmol/l)
was found [11]. FPG values were provided by the Clinical
Biochemistry Department of Nicosia General Hospital.
Cardiovascular disease (CVD) was defined as the presence
of coronary heart disease (history of myocardial infarc-
tion, ischemic heart disease, angina pectoris or surgical
history of either coronary artery bypass grafting or percu-
taneous transluminal coronary angioplasty) or a major or
minor stroke or peripheral artery disease [1].
Hyperlipidemia was considered present if the diagnosis of
hyperlipidemia was registered in the medical file, or if
patients were on lipid-lowering drugs (LLD) or if thereBMC Health Services Research 2008, 8:148 http://www.biomedcentral.com/1472-6963/8/148
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was at least one value of Total Cholesterol (TC) ≥190 mg/
dl (5 mmol/l) and/or a value of LDL-Cholesterol ≥115
mg/dl (3 mmol/l) and/or a measurement of Triglycerides
(TG) ≥150 mg/dl (1.7 mmol/l) documented in their med-
ical records within the year examined [1]. Lipid values
were provided by the Clinical Biochemistry Department
of Nicosia General Hospital. The biochemistry depart-
ment uses daily internal controls and participates in three
external quality assessment programs.
Medical diagnoses were coded according to the Interna-
tional Classification of Diseases, version 10 (ICD-10) [12]
and medications were coded using the fifth level of the
Anatomical Therapeutic Chemical system (ATC), version
2000 [13].
Information regarding smoking status of the patients was
not documented in the medical files and was obtained
through an interview questionnaire performed by the ten
trained nurses of the participating PCHCs. Patients were
categorized as 'current smoker', 'former smoker' or 'non-
smoker'.
Patient risk stratification
The cardiac risk was evaluated through the "SCORE risk
function" according to the Third Joint Task Force Euro-
pean guidelines on CVD prevention [1] for high risk
regions, as Cyprus, although a Mediterranean country is
classified as high risk. The chart comprises a table of the
following parameters: sex, smoking status, SBP, TC and
age. Risk was estimated by rounding a person's age to the
nearest shown on the chart, their TC level to the nearest
whole unit and their SBP to the nearest multiple of 20
mmHg [8]. Risk was defined in terms of absolute proba-
bility of developing a fatal cardiovascular event within 10
years and the threshold for high risk was defined as ≥5%.
Patients in whom the algorithm could not be applied due
to missing data on several risk factors (i.e. lipids, BP and
smoking) were excluded from SCORE calculation and
from further analysis on goal attainment. Patients were
categorized according to the priorities defined in the Euro-
pean guidelines for CVD prevention [1,9] into the follow-
ing risk groups: (1) patients with CVD (+/- DM); (2)
patients with DM (no CVD); 3) patients at high risk to
develop CVD (no CVD, no DM, SCORE ≥5%); (4)
patients with a low risk to develop CVD (no CVD, no DM,
SCORE <5%); (5) patients with missing data for risk cal-
culation.
Attainment goals for risk factors
To assess attainment goals for risk factors, the most recent
SBP and DBP, TC, LDL-cholesterol (LDL-C), HDL-choles-
terol (HDL-C) and TG values recorded in the medical
records were used. These were compared with the recom-
mendations in the European guidelines [1]. For patients
with DM2, FBG (fasting blood glucose) and HbA1c (gly-
cated haemoglobin) values were additionally used.
Medical management
The most updated medication lists were used for analysis
of management effectiveness. According to the European
guidelines, those patients with a 10 year risk ≥5% of hav-
ing a fatal CVD event together with SBP ≥140 mmHg and/
or TC ≥190 mg/dl (5 mmol/l) and/or LDL-C ≥115 mg/dl
(3 mmol/l) should take antihypertensive and/or LLD and
aspirin treatment [1]. For the high risk patients (SCORE
risk categories 1, 2, and 3) we compared current with rec-
ommended treatment patterns for BP and lipids according
to the European guidelines. We calculated a delta (Δ) per-
centage, which expresses the difference between recom-
mended and observed current drug use. A positive delta
percentage indicates that the recommended use exceeds
current use.
Statistical analysis
Descriptive analyses were used to evaluate the characteris-
tics of the total study sample. Continuous variables are
presented as means with standard deviations (SD) and
categorical variables as percentages. T-test was performed
to test for differences on continuous variables between
groups. All analyses were conducted using SAS (SAS Insti-
tute Inc.) version 9.1. P-values less than 0.05 were consid-
ered significant.
Ethics
Before initiation, the Ethics Committee of Cyprus
approved the study [14].
Results
Participants' characteristics
The characteristics of the patients enrolled in the study are
shown in Table 1. Women represented 62.4% of the over-
all population (n = 687). DM2 was present in 26.8% of
the patients (n = 295). Hypertension and hyperlipidemia
were present in 641 (79.5%) and 313 (38.8%) non-dia-
betic patients respectively. Smoking status was known in
364 patients (33.1%).
Implementation of SCORE risk chart
The SCORE risk chart was applicable to 157 patients with
multiple risk factors, whereas 563 patients (51.1%) were
unclassifiable [45.6% of men (n = 189), 54.4% of women
(n = 374)] due to missing data mostly on smoking habits
as shown in Table 1. Of patients with available data for
SCORE calculations, approximately 87% of men and 58%
of women aged 60 were classified as high risk, whereas
101 patients (18.8%) from those with available data for
SCORE calculation had 10-year risk for fatal CVD event
<5%.BMC Health Services Research 2008, 8:148 http://www.biomedcentral.com/1472-6963/8/148
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Goal attainment and patterns of medication use in 
primary and secondary prevention subgroups
As shown in Table 2, the LDL-C goal <100 mg/dl (2.5
mmol/l) was achieved in 28.6% of patients with CVD,
19.5% of patients with DM2 and 20.9% of those with
multiple risk factors for CVD. When we applied the more
stringent recommendations of the 2007 European guide-
lines [9], only 5% of the patients with CVD and 8% of
DM2 patients had LDL-C <80 mg/dl.
BP targets were achieved in 55.4%, 5.6% and 41.9%
respectively. Patterns of the gap between recommended
and current drug use are shown in Table 3. All delta per-
centages were positive for the three groups, indicating
under prescription of medication. The smallest gap was
observed for antihypertensive medication in patients with
CVD (Δ = 3.6%), the largest gap was observed among
non-diabetic high-risk patients for aspirin use (Δ = 89.2
%).
Discussion
Main findings
This was the first study in Cyprus on cardiovascular risk
stratification by means of the SCORE system according to
the European guidelines. The implementation of this risk
model in a selected cohort of primary care patients with
established risk factors for CVD has labelled a substantial
proportion as high risk individuals (overall 39.7%).
Almost 90% of men aged 55 and 57.8% of women aged
60 were classified as high risk. In a similar study by Getz
et al [15], 91.4% of men aged 55 and 57.3% of women at
age 60 were classified as high risk according to SCORE
chart, findings that are in accordance with those of our
study.
In addition, this study demonstrates a gap between rec-
ommended and current drug use for the high risk popula-
tion. Two studies from Norway [16,17] found that 42%
and 52% of men aged 45–64 respectively would be candi-
dates for antihypertensive or LLD treatment, whereas
according to another study [18], 29% of dyslipidemic
patients should receive LLD. In our study, the gap between
recommended and current antihypertensive use was
Table 1: Characteristics of the study population (N = 1101)
Characteristic Men (n = 414)
N (%)
Women (n = 687)
N (%)
Total (N = 1101)
N (%)
Mean ± SD
Age (years) 67 ± 10.7 67 ± 10.6 67 ± 11
Age groups (years)
≤64 158 (38.2) 276 (40.2) 434 (39.4)
≥65 255 (61.6) 410 (59.7) 665 (59.5)
Missing 1 (0.2) 1 (0.1) 2 (0.2)
Diagnoses
• DM2 134 (32.4) 161 (23.4) 295 (26.8)
• Hypertension 307 (74.2) 530 (77.1) 837 (76.0)
• Hyperlipidemia 144 (34.8) 264 (38.4) 408 (37.1)
SCORE risk category
1. CVD+/- DM2* 68 (16.4) 35 (5.1) 103 (9.4)
2. DM2 no CVD 114 (27.5) 146 (21.3) 260 (23.6)
3. High risk** 40 (9.7) 34 (4.9) 74 (6.7)
4. Low risk† 11 (2.7) 90 (13.1) 101 (9.2)
5. Unclassified risk status‡‡ 189 (45.7) 374 (54.4) 563 (51.1)
Smoking status
• Current smokers 31 (7.5) 10 (1.5) 41 (3.7)
• Former smokers 64 (15.5) 11 (1.6) 75 (6.8)
• Non-smokers 52 (12.6) 196 (28.5) 248 (22.5)
• Missing smoking status 267 (64.5) 470 (68.4) 737 (66.9)
CVD*: definitions see text; DM2: Type 2 Diabetes Mellitus
**Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of ≥5% for developing a fatal CVD event; Patients 
with TC ≥320 mg/dl (≥8 mmol/l) or LDL ≥240 mg/dl (≥6 mmlo/l) or BP ≥180/110 mmHg.
†Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of <5% for developing a fatal CVD event.
‡‡ Patients with neither CVD nor DM2 but with missing data on risk factors for score calculationBMC Health Services Research 2008, 8:148 http://www.biomedcentral.com/1472-6963/8/148
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larger in the diabetic group of patients (13.1%). The fact
that only 42% of patients with CVD were taking LLD and
even less (29%) achieved recommended LDL-C is a matter
of concern. In a study from Spain [19], 65% of patients
with CHD were on LLD and 31% of those achieved LDL-
C target whereas in a retrospective study by Straka et al
[20], 71% of patients with CHD were on LLD and 35% of
those had LDL <100 mg/dl. Harz et al [21] showed that
50% of patients with CHD were on LLD and one in three
reached lipid goal. According to the results of EUROA-
SPIRE [22] I and II, 54% of patients with established CHD
had BP off target (≥ 140/90 mmHg) as compared to
44.6% of our study patients of the similar group.
Regarding the diabetic population of the study 19.5%
achieved their LDL-C goal. In other studies [23-25] these
Table 2: Goal attainment of blood pressure and lipids in high-risk patients according to the European guidelines with respective mean 
values.
Parameters Mean ± SD Number of patients (%)
SCORE RISK CATEGORY 1 (CVD; n = 103)
TC (mg/dl), n = 42 207 ± 32.6
• <175 mg/dl (4.5 mmol/l) 7 (16.7)
• ≥175 mg/dl 35 (83.3)
• missing (% of total N) 61 (59.2)
LDL-C (mg/dl), n = 21 121 ± 36.9
• <100 mg/dl (2.5 mmol/l) 6 (28.6)
• ≥100 mg/dl 15 (71.4)
• missing (% of total N) 82 (79.6)
BP (mmHg), n = 83 132 ± 15.2 (SBP) 80 ± 6.6 (DBP)
• <140/90 mmHg 46 (55.4)
• ≥140/90 mmHg 37 (44.6)
• missing (% of total N) 20 (19.4)
SCORE RISK CATEGORY 2 (DM2, no CVD; n = 260)
TC (mg/dl), n = 136 216 ± 43.2
• <175 mg/dl (4.5 mmol/l) 23 (16.9)
• ≥175 mg/dl 113 (83.1)
• missing (% of total N) 124 (47.7)
LDL-C (mg/dl), n = 77 127 ± 36.0
• <100 mg/dl (2.5 mmol/l) 15 (19.5)
• ≥100 mg/dl 62 (80.5)
• missing (% of total N) 183 (70.4)
BP (mmHg), n = 213 138 ± 15.8 (SBP) 82 ± 7.4 (DBP)
• <130/80 mmHg 12 (5.6)
• ≥130/80 mmHg 201 (94.4)
• missing (% of total N) 47 (18.1)
HbA1c (%), n = 31 7.2 ± 1.3
• <7% 12 (38.7)
• ≥7% 19 (61.3)
• missing (% of total N) 229 (88.1)
SCORE RISK CATEGORY 3 (SCORE ≥5%; n = 74)
TC (mg/dl), n = 71 241 ± 76.3
• <175 mg/dl (4.5 mmol/l) 8 (11.3)
• ≥175 mg/dl 63 (88.7)
• missing (% of total N) 5 (6.8)
LDL-C (mg/dl), n = 43 144 ± 49.6
• <100 mg/dl (2.5 mmol/l) 9 (20.9)
• ≥100 mg/dl 34 (79.1)
• missing (% of total N) 33 (43.5)
BP (mmHg), n = 74 142 ± 20.0 (SBP) 82 ± 9.1 (DBP)
• <140/90 mmHg 31 (41.9)
• ≥140/90 mmHg 43 (58.1)
• missing (% of total N) 0 (0)
TC: Total Cholesterol; LDL-C: Low Density Lipoprotein Cholesterol: BP: Blood Pressure, SBP: Systolic Blood Pressure, DBP: Diastolic Blood 
Pressure, HbA1c: Glycated hemoglobinBMC Health Services Research 2008, 8:148 http://www.biomedcentral.com/1472-6963/8/148
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percentages ranged from 16.5% to 53%, whereas in a
Greek study [26] 17.5% of diabetic patients achieved LDL-
C <100 mg/dl. BP control was particularly low among
patients with DM2 (7.5%) as compared to other studies
[23,25,27-29], with percentages ranging between 10.3%
and 35%. Women with DM2 had worse mean FBG (160
vs 140 mg/dl, p = 0.044) as compared to diabetic men, a
findings also supported by an Italian study [25].
Limitations
Several limitations of our study should be noted. This
study examined a selected population of patients with
already known risk factors for CVD (hypertension, hyper-
lipidemia, DM2) and was not performed in healthy indi-
viduals. Thus, our findings are restricted to this clinical
segment of the population. Also, the study was performed
in only four PCHCs from the total of fifteen in Nicosia
area and in only one area of the island. Results must thus,
be interpreted with caution and cannot be generalised for
the entire population of the island.
Furthermore, many of the patients were already receiving
antihypertensive or LLD treatment which could have
modified their risk profile at the time of their risk assess-
ment. In addition, the SCORE risk chart could not be cal-
culated in over 50% of the participants due to
underreporting of clinical information in the medical
files. As a result, the 10-year risk for a fatal cardiovascular
event is unknown for more than half of the studied
patients and therefore we can not draw conclusion for the
remaining population of the study.
Implications of the study to national health care policy
There are some important messages derived from this
study that should convey to health policy makers who are
responsible for the design and implementation of the new
NHS in Cyprus. The fact that GPs underreport clinical
information (smoking behaviour, lipid values and BP) is
indeed a matter of concern. It should be stressed out that
a major step in improving the management of CVD risk
factors is to accurately report them and treat them. How-
ever, there have not been any studies so far in the PHC set-
ting of Cyprus to assess the level of documentation of
clinical information by the GPs. We can either assume
that GPs do perform blood tests, measure BP and ask
about the smoking habits of their patients but they do not
document this information in the medical files or that
they simply do not perform them. These however, are
only assumptions and further studies are needed in order
to reach safe conclusion. Also, as shown from our results,
GPs do not follow clinical practice guidelines in their eve-
ryday practice for the management of patients with com-
mon chronic conditions. This was indicated from the
under-treatment of high risk patients as well as from gaps
in goal attainment. Potential barriers could be administra-
tive, educational and time pressures. These issues could be
addressed through introduction of organisational systems
to support the management of patients with chronic dis-
Table 3: Proportion of high risk patients on treatment as recommended by the European guidelines†. Proportion of low risk patients 
and of unclassified patients on treatment.
SCORE risk category 
Treatment
(1) CVD (n=103) (2) DM2 (n=260) (3) SCORE ≥5% (n=74) (4) SCORE <5% 
(n=101)
(5) 
Unclassified(n=563)
N (%) Δ(%) N (%) Δ(%) N (%) Δ(%) N (%) N (%)
ANTIHYPERTENSIV
ES
3.6 13.1 6.7
• Current 34 (41.0) 86 (40.4) 38 (51.4) 71 (70.3) 382 (67.9)
• Recommended 37 (44.6) 114 (53.5) 43 (58.1)) - -
LLD 30.2 38.9 47.9
• Current 18 (41.9) 50 (36.8) 27 (38.0) 46 (45.5) 173 (30.7)
• Recommended 31 (72.1) 103 (75.7) 61 (85.9) - -
ASPIRIN 53.4 87.7 89.2
• Current 48 (46.6) 32 (12.3) 8 (10.8) 25 (24.8) 13(2.3)
• Recommended 103 (100) 260 (100) 74 (100) - -
SCORE risk categories:
(1): Patients with CVD +/- DM2
(2): Patients with DM2 (no CVD)
(3): Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of ≥5% for developing a fatal CVD event; Patients 
with TC ≥320 mg/dl (≥8 mmol/l) or LDL ≥240 mg/7 dl (≥6 mmlo/l) or BP ≥180/110 mmHg.
(4): Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of <5% for developing a fatal CVD event.
(5): Patients with neither CVD nor DM2 but with missing data on risk factors for score calculation
†Values are for those patients with available dataBMC Health Services Research 2008, 8:148 http://www.biomedcentral.com/1472-6963/8/148
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eases (i.e. registries, computerised recall and reminder sys-
tems) as well as effective charting systems (e.g. flow
sheets) to improve quality assurance and documentation
[29].
Furthermore, our study was performed before the publica-
tion of the recent European guidelines [1,9] and therefore
GPs were unaware of the recommendations stated in the
guidelines. However, our intention was to have an initial
evaluation of the care delivered in the PHC setting of
Cyprus in order to identify failures and stimulate for
actions before the introduction of the new NHS. This
study served as the first part of a quality project that was
followed by the implementation of a multifaceted inter-
vention in DM2 patients.
Finally, the fact that Cyprus is included in the high risk
regions for CVD and whether these guidelines overesti-
mate risk in the general population are matters that
should raise discussion. So far, there are no national
guidelines for CVD prevention and only recently the
Cyprus College of Cardiology adapted the Greek version
of the European guidelines. Until epidemiological studies
are performed addressing the above mentioned issues,
including the assessment of the risk level of the popula-
tion at risk for CVD, current guidelines could and should
serve as a tool to GPs for prioritising patients in order to
address the role of lifestyle changes, the management of
cardiovascular risk factors and the use of other prophylac-
tic drug therapies in the prevention of clinical CVD.
Conclusion
Implementation of the European guidelines in patients
with risk factors for CVD in the Primary Care in Cyprus
has classified a substantial proportion at high risk for fatal
cardiovascular event and revealed suboptimal quality of
care with regard to risk factor registration, medical treat-
ment and achievement of treatment targets. The study
results could act as a stimulus to improve Cypriot primary
care for cardiovascular disease.
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